Authors: Faizan Khan; Tobias Tritschler; Miriam Kimpton; Philip S. Wells; Clive Kearon; Jeffrey I. Weitz; Harry R. Büller; Gary E. Raskob; Walter Ageno; Francis Couturaud; Paolo Prandoni; Gualtiero Palareti; Cristina Legnani; Paul A. Kyrle; Sabine Eichinger; Lisbeth Eischer; Cecilia Becattini; Giancarlo Agnelli; Maria Cristina Vedovati; Geert-Jan Geersing; Toshihiko Takada; Benilde Cosmi; Drahomir Aujesky; Letizia Marconi; Antonio Palla; Sergio Siragusa; Charlotte A. Bradbury; Sameer Parpia; Ranjeeta Mallick; Anthonie W.A. Lensing; Martin Gebel; Michael A. Grosso; Kednapa Thavorn; Brian Hutton; Gregoire Le Gal; Dean A. Fergusson; Marc A. Rodger

Venue: Annals of Internal Medicine

Type: Publication

Abstract: The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain.To determine the incidence of major bleeding during extended anticoagulation of up to 5 years among patients with a first unprovoked VTE, overall, and in clinically important subgroups.MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from inception to 23 July 2021.Randomized controlled trials (RCTs) and prospective cohort studies repo... (read more)

DOI: 10.48350/159493